This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n8http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216275%3A25310%2F08%3A00007777%21RIV09-MSM-25310___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216275%3A25310%2F08%3A00007777%21RIV09-MSM-25310___
rdf:type
skos:Concept n12:Vysledek
dcterms:description
Alzheimerova choroba je nejběžnější neurodegenerativní onemocnění klinicky charakterizované významným poklesem kognitivních funkcí, ztrátou paměti a schopnosti se učit, společně s poklesem schopnosti vykonávat běžné denní aktivity. Významnými neuropsychiatrickými symptomy jsou apatie, podrážděnost, deprese atd. Farmakoterapie Alzheimerovy choroby se za posledních deset let posunula od užívání psychotropních léčiv na uklidnění k léčivům zaměřeným na náhradu neurotransmiterů. Jenom jedna skupina léčiv byla rozsáhle hodnocena v klinických studiích s pacienty s Alzheimerovou chorobou a schválena FDA pro léčbu Alzheimerovy choroby. Jsou to inhibitory cholinesteráz, které mají významný vliv na stav kognitivních funkcí u pacientů s Alzheimerovou chorobou. Alzheimer´s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer´s disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer´s disease and is approved by the US Food and Drug Administration for Alzheimer´s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer´s disease. Alzheimer´s disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimer´s disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimer´s disease and is approved by the US Food and Drug Administration for Alzheimer´s disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimer´s disease.
dcterms:title
Cholinesterázy a cholinesterázové inhibitory Cholinesterases and Cholinesterase Inhibitors Cholinesterases and Cholinesterase Inhibitors
skos:prefLabel
Cholinesterases and Cholinesterase Inhibitors Cholinesterases and Cholinesterase Inhibitors Cholinesterázy a cholinesterázové inhibitory
skos:notation
RIV/00216275:25310/08:00007777!RIV09-MSM-25310___
n3:aktivita
n16:Z
n3:aktivity
Z(MSM0021627502)
n3:cisloPeriodika
4
n3:dodaniDat
n11:2009
n3:domaciTvurceVysledku
n4:6965938 n4:6973442
n3:druhVysledku
n9:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
359827
n3:idVysledku
RIV/00216275:25310/08:00007777
n3:jazykVysledku
n6:eng
n3:klicovaSlova
Alzheimer´s disease; cholinesterases; cholinesterase inhibitors
n3:klicoveSlovo
n14:cholinesterases n14:cholinesterase%20inhibitors n14:Alzheimer%C2%B4s%20disease
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[D784D39448AB]
n3:nazevZdroje
Current Enzyme Inhibition
n3:obor
n7:CE
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
2
n3:rokUplatneniVysledku
n11:2008
n3:svazekPeriodika
4
n3:tvurceVysledku
Komers, Karel Štěpánková, Šárka
n3:zamer
n8:MSM0021627502
s:issn
1573-4080
s:numberOfPages
12
n17:organizacniJednotka
25310